BACKGROUND: Many pulmonary emboli (PE) are detected unsuspectedly in lung cancer patients. The purpose of our study was to retrospectively evaluate the role of anticoagulation therapy for unsuspected PE in lung cancer patients. We also aimed to evaluate risk factors associated with the development of PE as well as the prognostic power of PE in lung cancer patients. PATIENTS AND METHODS: The Samsung Medical Information System was used to evaluate predictors and prognosis of PE in lung cancer patients. We found patients with PE using the Radiation Interpretation Registry and reviewed their medical records. RESULTS: Among 8014 lung cancer patients, PE developed in 180 patients (cumulative incidence rates=2.2%). Metastasis and prior history of chemotherapy were significant predictors of the development of PE. Pulmonary embolism detected within 3 months after diagnosis of lung cancer was a significant poor prognostic factor (hazard ratio [HR], 1.5; 95% CI, 1.1-2.0) in the complete lung cancer cohort. One hundred thirteen (63%) out of total 180 PE patients were incidentally found to have PE. Among the 113 patients with unsuspected PE, 62 patients (55%) did not receive anticoagulation therapy, and died sooner than those who received anticoagulation therapy for unsuspected PE (HR, 4.1; 95% CI, 2.3-7.6). CONCLUSION: Anticoagulation therapy for unsuspected PE is associated with increased overall survival in lung cancer patients. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND: Many pulmonary emboli (PE) are detected unsuspectedly in lung cancerpatients. The purpose of our study was to retrospectively evaluate the role of anticoagulation therapy for unsuspected PE in lung cancerpatients. We also aimed to evaluate risk factors associated with the development of PE as well as the prognostic power of PE in lung cancerpatients. PATIENTS AND METHODS: The Samsung Medical Information System was used to evaluate predictors and prognosis of PE in lung cancerpatients. We found patients with PE using the Radiation Interpretation Registry and reviewed their medical records. RESULTS: Among 8014 lung cancerpatients, PE developed in 180 patients (cumulative incidence rates=2.2%). Metastasis and prior history of chemotherapy were significant predictors of the development of PE. Pulmonary embolism detected within 3 months after diagnosis of lung cancer was a significant poor prognostic factor (hazard ratio [HR], 1.5; 95% CI, 1.1-2.0) in the complete lung cancer cohort. One hundred thirteen (63%) out of total 180 PE patients were incidentally found to have PE. Among the 113 patients with unsuspected PE, 62 patients (55%) did not receive anticoagulation therapy, and died sooner than those who received anticoagulation therapy for unsuspected PE (HR, 4.1; 95% CI, 2.3-7.6). CONCLUSION: Anticoagulation therapy for unsuspected PE is associated with increased overall survival in lung cancerpatients. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: M Carrier; A Lazo-Langner; S Shivakumar; V Tagalakis; P L Gross; N Blais; C A Butts; M Crowther Journal: Curr Oncol Date: 2015-02 Impact factor: 3.677
Authors: Atul B Shinagare; Mengye Guo; Hiroto Hatabu; Katherine M Krajewski; Katherine Andriole; Annick D Van den Abbeele; Pamela J DiPiro; Mizuki Nishino Journal: Cancer Date: 2011-02-11 Impact factor: 6.860
Authors: Marco Paolo Donadini; Francesco Dentali; Alessandro Squizzato; Luigina Guasti; Walter Ageno Journal: Intern Emerg Med Date: 2014-03-25 Impact factor: 3.397